Home › Chronic Lymphocytic Leukemia › Minnesota
Chronic Lymphocytic Leukemia clinical trials in Minnesota
30 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Minnesota.
Cities in Minnesota
- Rochester20 studies
- Minneapolis8 studies
- Duluth5 studies
- Brooklyn Park4 studies
- Bloomington3 studies
- Saint Paul3 studies
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04269902A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Avera Cancer Institute - Marshall ( Site 5462), Marshall
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05947851A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05091424A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Minnesota Oncology Hematology, P.A., Coon Rapids
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07218341Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- and 49 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- and 13 more
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Nov 3, 2026 · NCT07321652Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Nov 2, 2026 · NCT00626496Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT03516617Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06943872Wisconsin Ginseng for Decreasing Cancer Related Fatigue
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- and 11 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06395441A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Regions Hospital ( Site 0042), Saint Louis Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07271667CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 9, 2026 · NCT04892277The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Mayo Clinic in Rochester, Rochester
RecruitingHealthy volunteers welcome
Ages 18 to 80 · All sexes · Updated Apr 9, 2026 · NCT05876923Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
- Mayo Clinic in Rochester, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Mar 31, 2026 · NCT06536452A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Mayo Clinic- Minnesota, Rochester
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Mayo Clinic- Minnesota, Rochester
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
All ages · All sexes · Updated Feb 27, 2026 · NCT06151730Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- St. Lukes Hospital of Duluth /ID# 250021, Duluth
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04895436Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.